Company intelligence / Profile preview
Actinium Pharmaceuticals, Inc.
- Ownership
- Public · ATNM
- Employees
- ~37
- Development stage
- Phase 3
Overview
Actinium has positive Phase 3 SIERRA trial results for Iomab-B. The company is advancing multiple clinical programs including Actimab-A in various combinations for AML and solid tumors, and Iomab-ACT for cell and gene therapy conditioning. Clinical data for multiple programs is expected throughout 2025.
- Therapeutic areas
- OncologyHematology
- Modalities
- Antibody Radiation Conjugates (ARCs)Targeted radiotherapies
- Industry
- Biotech
Drug pipeline
15 assets14 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $38.6M
- Total revenue
- $35M
- Enterprise value
- $3.5M
Beyond the preview
Go deeper on Actinium Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Actinium Pharmaceuticals, Inc..